Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to investigate Bucillamine's potential for boosting anti-tumor effects in patients with advanced solid tumors

Next Previous
Trial Profile

A clinical study to investigate Bucillamine's potential for boosting anti-tumor effects in patients with advanced solid tumors

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bucillamine (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 28 Apr 2025 New trial record
  • 10 Apr 2025 According to a Revive Therapeutics media release, the company has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute for investigating Bucillamine's potential for solid tumors, confirming its anti-inflammatory and antioxidant effects, since inflammation and oxidative stress are known to be contributing factors for initiating cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top